Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) shares traded up 4% during trading on Tuesday . The company traded as high as $1.87 and last traded at $1.81. 5,968 shares changed hands during trading, a decline of 55% from the average session volume of 13,259 shares. The stock had previously closed at $1.74.
Alaunos Therapeutics Stock Performance
The business’s 50 day simple moving average is $2.11 and its 200-day simple moving average is $2.85.
Alaunos Therapeutics Company Profile
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Further Reading
- Five stocks we like better than Alaunos Therapeutics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Financial Services Stocks Investing
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Market Cap Calculator: How to Calculate Market Cap
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
